Proactive Investors
29 Sept 2026, 07:13 UTC · 1h ago
Verdict
Headline takes no side. We score DEC +0.70 across three claims — strongly bullish.
+0.70strongly bullish
More positive than 82% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 1 new · 2 priced in
Solvonis analysis of its SVN-001 treatment showed a 67% reduction in heavy drinking days compared with placebo measured in weeks 17 to 20.
Newpublished 29 Sep 2026
More positive than 93% of claims this week
Solvonis is recruiting 280 patients for a UK phase III trial of SVN-001 co-funded by the National Institute for Health and Care Research.
Priced in
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 79% of claims this week
SVN-002, an oral film version of esketamine, is moving toward phase II trials in the US.
Priced inno timing evidence in text
More positive than 66% of claims this week
Which stocks this story touches
More positive than 82% of ticker scores this week
Agreed to its largest-ever acquisition, which is expected to boost production by approximately 35%.
More positive than 77% of ticker scores this week
Positive phase II trial analysis showing a significant reduction in heavy drinking days for its alcohol treatment.
More positive than 71% of ticker scores this week
Secured a significant £110 million contract for improvement works.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Proactive Investors
50m ago
—
DEC hasn't traded since this ran. Last close $13.57 (Sep 28); the reaction starts at the next open.
DEC chart →
